PBPK modeling of ivermectin—Considerations for the purpose of developing alternative routes to optimize its safety profile by Karen Rowland Yeo, David Wesche

Get full text

Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders by Craig R. Rayner, Patrick F. Smith, Kevin Hershberger, David Wesche

Get full text

Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus d... by Ruanne V. Barnabas, Elizabeth Brown, Anna Bershteyn, R. Scott Miller, Mark Wener, Connie Celum, Anna Wald, Helen Chu, David Wesche, Jared M. Baeten, for the Hydroxychloroquine COVID-19 PEP Study Team

Get full text

Development and application of a PBPK modeling strategy to support antimalarial drug development by Nada Abla, Eleanor Howgate, Karen Rowland‐Yeo, Maurice Dickins, Mackenzie C. Bergagnini‐Kolev, Kuan‐Fu Chen, Savannah McFeely, Jennifer J. Bonner, Laura G. A. Santos, Nathalie Gobeau, Howard Burt, Zoe Barter, Hannah M. Jones, David Wesche, Susan A. Charman, Jörg J. Möhrle, Jeremy N. Burrows, Lisa M. Almond

Get full text

Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. by Xin Hui S Chan, Yan Naung Win, Ilsa L Haeusler, Jireh Y Tan, Shanghavie Loganathan, Sompob Saralamba, Shu Kiat S Chan, Elizabeth A Ashley, Karen I Barnes, Rita Baiden, Peter U Bassi, Abdoulaye Djimde, Grant Dorsey, Stephan Duparc, Borimas Hanboonkunupakarn, Feiko O Ter Kuile, Marcus V G Lacerda, Amit Nasa, François H Nosten, Cyprian O Onyeji, Sasithon Pukrittayakamee, André M Siqueira, Joel Tarning, Walter R J Taylor, Giovanni Valentini, Michèle van Vugt, David Wesche, Nicholas P J Day, Christopher L-H Huang, Josep Brugada, Ric N Price, Nicholas J White

Get full text